RT Journal Article
SR Electronic
T1 Distinct baseline immune characteristics associated with responses to conjugated and unconjugated pneumococcal polysaccharide vaccines in older adults
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.04.16.23288531
DO 10.1101/2023.04.16.23288531
A1 Ravichandran, Sathyabaarathi
A1 Erra-Diaz, Fernando
A1 Karakaslar, Onur E.
A1 Marches, Radu
A1 Kenyon-Pesce, Lisa
A1 Rossi, Robert
A1 Chaussabel, Damien
A1 Pascual, Virginia
A1 Palucka, Karolina
A1 Paust, Silke
A1 Nahm, Moon H.
A1 Kuchel, George A.
A1 Banchereau, Jacques
A1 Ucar, Duygu
YR 2023
UL http://medrxiv.org/content/early/2023/04/19/2023.04.16.23288531.abstract
AB Pneumococcal infections cause serious illness and death among older adults. A capsular polysaccharide vaccine PPSV23 (Pneumovax®) and a conjugated polysaccharide vaccine PCV13 (Prevnar®) are used to prevent these infections, yet underlying responses, and baseline predictors remain unknown. We recruited and vaccinated 39 older adults (>60 years) with PPSV23 or PCV13. Both vaccines induced strong antibody responses at day 28 and similar plasmablast transcriptional signatures at day 10, however, their baseline predictors were distinct. Analyses of baseline flow cytometry and RNA-seq data (bulk and single cell) revealed a novel baseline phenotype that is specifically associated with weaker PCV13 responses, characterized by i) increased expression of cytotoxicity-associated genes and increased CD16+ NK frequency; ii) increased Th17 and decreased Th1 cell frequency. Men were more likely to display this cytotoxic phenotype and mounted weaker responses to PCV13 than women. Baseline expression levels of a distinct gene set was predictive of PPSV23 responses. This first precision vaccinology study for pneumococcal vaccine responses of older adults uncovered novel and distinct baseline predictors that might transform vaccination strategies and initiate novel interventions.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT03104075Funding StatementThis study was funded by the financial support of the National Institutes of Health (NIH) grants under award number - R01AG052608 (to J.B.), U01AI165452, P30AG067988 Older Americans Independence Pepper Center (to G.A.K., R.M., D.U.) and R01AI142086 (to DU, GAK).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All studies were conducted following approval by the Institutional Review Board of UConn Health Center (IRB Number: 16-071J-1) and registration on ClinicalTrials.gov (NCT03104075).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.